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Objectives: To assess the efficacy and tolerability of a fixed-dose combination of olmesartan 
and amlodipine in an unselected population of patients in primary care and to compare the 
results with recent randomized controlled trial evidence.
Methods: A multicenter, noninterventional, noncontrolled observational study with 8241 
hypertensive patients seen by 2187 physicians in daily practice. Blood pressure (BP) reduction, 
comorbid disease, pharmacotherapy, and tolerability were documented over a 12–18-week 
observational period.
Results: Patients had a mean age of 62.8 ± 11.8 years (48.1% female), and 74.8% had at 
least one comorbid risk factor or condition. In total, 51.3% received olmesartan-amlodipine 
20/5 mg, 30.6% received 40/5 mg, and 17.9% received 40/10 mg at baseline, mostly 
because of lack of efficacy on prior antihypertensive therapy (73.8%). BP at baseline was 
161.8 ± 16.6/93.6 ± 10.2 mmHg (39.8% had Grade 2 hypertension), and the observed BP 
reduction was −29.0 ± 17.1/−13.5 ± 10.9 mmHg (P , 0.0001), with a significant correlation 
between BP at baseline and BP reduction (Spearman’s Rho −0.811 for systolic BP and −0.759 
for diastolic BP). BP reduction appeared to be dependent on dose and prior antihypertensive 
therapy, but not on age, gender, body mass index, duration of hypertension, or the presence of 
diabetes. At the final visit, 69.4% (4.3% at baseline) were controlled (,140/90 mmHg). Adverse 
drug reactions were observed in 2.76% of the study population; 94.25% of these adverse drug 
reactions were judged as nonserious events, and 31.5% of all adverse drug reactions reported 
were peripheral edema.
Conclusion: The fixed-dose olmesartan-amlodipine combination was effective and well toler-
ated in an unselected population of patients in primary care practice. These results confirm prior 
randomized controlled trial evidence.
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Introduction
The combination of two antihypertensive drugs is recommended by the European Soci-
ety of Hypertension (ESH)/European Society of Cardiology (ESC)1,2 in patients with 
blood pressure (BP) not adequately controlled with antihypertensive monotherapy or 
as first-line therapy in patients at high risk. Blockers of the renin–angiotensin system, 
being the foundation of antihypertensive therapy in .50% of patients, are recommended 
to be combined with either thiazide diuretics (hydrochlorothiazide) or calcium chan-
nel blockers. Within this context, fixed-dose combinations offer the advantage of easy 
once-daily dosing which has been shown to improve patient compliance. While there 
was a preference for thiazide-type diuretics in older recommendations, recent data 
from the ACCOMPLISH (Avoiding Cardiovascular Events in Combination Therapy Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in Patients Living with Systolic Hypertension) study3 have 
resulted in a shift of this preference.2 In ACCOMPLISH, 
a fixed combination of an angiotensin-converting enzyme 
(ACE) inhibitor with hydrochlorothiazide was compared with 
a respective combination incorporating amlodipine, resulting 
in a significant reduction of cardiovascular morbidity and 
mortality with the amlodipine combination.
In response to a rising demand for highly effective and 
tolerable fixed-dose combinations with amlodipine, a combi-
nation of olmesartan-amlodipine was developed that was able 
to reduce BP by −30.1/−19.0 mmHg in doses up to 40/10 mg 
in a recent study.4 Almost maximal BP reduction was achieved 
as early as four weeks after treatment initiation and was sus-
tained throughout the eight-week study period. Tolerability 
was good, with a reduction of incidence of edema, known to 
be increased with amlodipine monotherapy at high doses. 
Fixed-dose combinations of antihypertensive drugs improve 
patient compliance which, in turn, is associated with a reduc-
tion in hospitalization and cardiovascular events.5,6
These results prompted us to question whether the 
efficacy and safety results seen in this double-blind ran-
domized clinical trial would be preserved in an open-label, 
noninterventional, observational study in primary care. This 
comparison is of particular importance because patients with 
unusual characteristics (eg, very old/young, very obese/slim, 
those with abundant concomitant medication) are usually 
excluded from randomized clinical trials, but are not infre-
quently encountered in primary care practice.
Patients and methods
SERVE (DE-SEV-02-08-DE) was a noninterventional, 
noncontrolled, prospective study in primary care practice in 
Germany. It was part of a European project including 15,000 
patients. Participating practices were sampled at random from 
specialists in general medicine, internal medicine, cardiology, 
and practitioners from all regions defined by the Institute of 
Medical Statistics. The study was conducted according to local 
laws and regulations (§67 (6) Arzneimittelgesetz, AMG) and 
the FSA Code (Freiwillige Selbstkontrolle für die Arzneimit-
telindustrie e.V .), and was duly notified to the federal authorities 
(Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) 
and the federal panel doctors’ association (Kassenärztliche 
Bundesvereinigung, KBV). Ethics committee approval and 
written patient informed consent were obtained.
Patients
Patients showing primary arterial hypertension and in 
whom previous pharmacotherapy did not reach target BP 
recommended by the ESH were identified. Beyond these cri-
teria, physicians were free to select patients within the scope 
of drug licensing, ie, no other inclusion and exclusion criteria 
were defined. They were also allowed to adjust the dosage of 
the drug and of any concomitant medication throughout the 
duration of the study according to patients’ needs.
Recording of data
At the enrolment visit, demographic data and data relating 
to the presence of hypertension (BP, heart rate, target BP 
achievement, and duration of hypertension) were obtained. 
Patient history including further concomitant cardiovascu-
lar risk factors and disease (metabolic syndrome, diabetes 
mellitus, stable angina pectoris, left ventricular hypertrophy, 
myocardial infarction, stroke/transitory ischemic attack, 
peripheral arterial disease, reduction of kidney or liver 
function, and smoking) was documented, along with disease 
duration. With respect to pharmacotherapy, previous/
concomitant antihypertensive therapy and concomitant 
non antihypertensive medication were recorded. Finally, the 
reason for switching to the fixed combination of olmesartan-
amlodipine was documented.
At the optional checkup visits at 4–6 and 8–12 weeks and 
the final visit at 12–18 weeks, adverse events, changes in BP, 
target BP achievement, and physician assessment of patient 
compliance, effectiveness, and tolerability (very good, good, 
satisfactory, insufficient) were obtained.
Physicians were asked to document patients who were 
being treated with olmesartan-amlodipine (20/5 mg, 
40/5 mg, 40/10 mg) because of inadequately controlled 
primary arterial hypertension. The documentation forms 
were recorded by Christine Franzen Consulting, a Clinical 
Research Organization in Stolberg, Germany. Data were 
examined for their plausibility in all documentation forms. 
Five percent of the participating physicians underwent 
monitoring of their documentation by fax. The patients 
were recorded in pseudonymized form, ie, only the age and 
gender of the patient were recorded, and all data collected 
during the observation period were treated confidentially. 
Data were electronically stored in accordance with data 
protection provisions. An honorarium for the documenta-
tion of eligible patients was paid in accordance with the 
official scale of physicians’ fees (Gebührenordnung für 
Ärzte [GOÄ]).
Adverse drug reactions
Adverse drug reactions were explicitly asked about at each 
follow-up visit and recorded in detail (eg, nature, date, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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duration, result, and causal relationship with therapy). All 
physicians were asked to report serious adverse events 
to the pharmaceutical manufacturer immediately, which 
in turn notified the BfArM in accordance with legal 
requirements.
statistical analysis
The statistical analysis was descriptively conducted, 
exploratively assessed, and then produced in tabular and 
graphic form. For categoric data, absolute and relative 
frequencies and, for continuous variables, the average 
and standard deviation were calculated. SAS software 
(v. 9.2 SAS Institute, Cary, NC) was used for the statistical 
analyses. The Spearman’s Rho was used for rank correlations 
(relationship of initial BP to reduction in BP). In order to 
be able to record rare adverse drug reactions, the number of 
cases was set at 8000 patients, which allowed adverse drug 
reactions up to an incidence of 0.1% to be recorded with a 
probability of almost 100% and adverse drug reactions with 
an incidence of 0.01% and a probability of 55.1%.
Results
Patient characteristics
A total of 8241 patients were identified by 2187 physicians 
between January and December 2009, of whom 8237 had 
received an olmesartan-amlodipine fixed combination (safety 
population). Patients had a mean age of 62.8 ± 11.8 years 
(48.1% female). All but one patient had arterial hypertension 
(99.99%), and 47.5% for more than five years. See Table 1 
for further details of patient characteristics. A total of 74.8% 
of patients had at least one cardiovascular risk factor or had 
comorbid cardiovascular disease (mean number 1.9 ± 2.3, 
Figure 1), with diabetes mellitus (33.1%), metabolic 
syndrome (30.0%), and smoking (24.9%) being the most 
frequent.
Antihypertensive treatment  
at baseline and during follow-up
In total, 7511/8235 (91.2%) of patients had received any prior 
antihypertensive therapy. An olmesartan-amlodipine fixed-
dose combination was frequently introduced in preference to 
ACE inhibitors, calcium channel blockers, and angiotensin 
receptor blockers (Table 2). After initiation, 51.3% received 
olmesartan-amlodipine 20/5 mg, 30.6% received 40/5 mg, 
and 17.9% received 40/10 mg. Most patients (73.8%) were 
switched because of lack of efficacy and 17.3% because of lack 
of tolerability on prior therapy, 14.2% because of insufficient 
compliance, and 17.4% were switched from a free combination 
to a fixed combination of both agents (13.8% guideline recom-
mendation, 2.6% missing; multiple answers possible).
The mean duration of exposure was 114.1 ± 34.5 days 
(median 110 [interquartile range 93–128]). Patient compli-
ance was regarded by the physicians to be very good in 
66.7% or good in 28.0% (total of 94.7%), but some patients 
were switched by the treating physicians between dose 
combinations (Table 3). In total, 75.1% received their initial 
fixed-dose combination until study end, 24.9% being either 
up- or downtitrated.
BP at baseline and during follow-up
Mean BP at baseline was 161.8 ± 16.6/93.6 ± 10.2 mmHg 
(pulse pressure 68.2 ± 14.7), the majority being   classified to 
Table 1 characteristics of patient safety population
Data available n Value
Age (mean ± sD, years) 8237 62.8 ± 11.8
  Age $ 65 years 8237 3841 46.6
Female (%) 8237 3966 48.1
BMi (mean ± sD; kg/m2) 8157 29.0 ± 4.7
  Obesity (%) 8157 2835 34.8
Waist circumference
  Men (% $ 102 cm) 3570 2119 59.4
  Women (% $ 88 cm) 3242 2567 79.2
Hypertension (%) 8237 8236 99.9
 . 5 years (%) 8009 3801 47.5
Abbreviations: sD, standard deviation; BMi, body mass index.
Table 2 Antihypertensive therapy (safety population; multiple 
answers possible)
Data 
available
Baseline After 
initiation
n % n %
Beta-blockers 8237 3431 41.7 2463 29.9
Diuretics 8237 2561 31.1** 1661 20.2
Ace inhibitors 8237 3567 43.3 534 6.5
calcium channel 
blockers
8237 3314 40.2** 511 6.2
Amlodipine 8237 2360 28.7 343 4.2
Angiotensin  
receptor blockers
8237 3155 38.3 514 6.2
Olmesartan 8237 1288 15.6 277 3.4
Others* 8237 1286 15.6 922 11.2
Olmesartan-
amlodipine 20/5
8237 n.a. n.a. 4232 51.3
Olmesartan- 
amlodipine 40/5
8237 n.a. n.a. 2526 30.6
Olmesartan- 
amlodipine 40/10
8237 n.a. n.a. 1479 17.9
Notes: *Central and peripheral acting antiadrenergic drugs/alpha-blockers/vasodilators/
others; **1935 patients received fixed-dose combinations of renin angiotensin system 
blocking agents with either diuretics or calcium channel blockers.
Abbreviations: ACE, angiotensin-converting enzyme; n.a., not applicable.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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have ESH/ESC Grade 2 hypertension (39.8%); 18.3% and 
18.6% had Grade 1 or Grade 3 hypertension, respectively, 
and 19.1% had isolated systolic hypertension. There was an 
overall mean BP reduction of 29.0 ± 17.1/13.5 ± 10.9 mmHg 
(P , 0.0001 versus baseline; pulse pressure 15.7 ± 15.0, 
P , 0.0001 versus baseline), that increased dependent on 
initial BP classification (Figure 2). BP reduction was most 
pronounced in patients with Grade 3 hypertension (−48.3 ± 
16.9/−22.6 ± 11.4 mmHg, P , 0.0001 versus baseline). 
Accordingly, there was a clear correlation between   systolic BP 
reduction and systolic BP at baseline (Spearman’s Rho −0.811), 
diastolic BP reduction and diastolic BP at   baseline   (Spearman’s 
Rho −0.759), and pulse pressure reduction and pulse pressure 
at baseline (Spearman’s Rho −0.804).
BP reduction at the final visit was also dependent 
on the dose employed (Table 4). Using olmesartan-
amlodipine  20/5  mg,  a  mean  BP  reduction  of 
−27.6 ± 16.3 mmHg/−13.2 ± 10.6 mmHg was achieved, 
that was increased up to −31.0 ± 18.8 mmHg/−14.1 ± 11.7 
mmHg with olmesartan-amlodipine 40/10 mg.
Patient characteristics, including age, body mass index, 
duration of hypertension (except for patients with a short 
duration in which BP lowering was enhanced) and the 
presence of diabetes had no substantial influence on the 
33.1
30.0
24.9
15.7
10.9
10.3
9.3
9.0
8.4
7.1
5.0
23.4
25.2
52.1
22.7
Diabetes mellitus
0.0 10.0 20.0 30.0 40.0 50.0 60.0
Metabolic syndrome
Smoking
LVH
Stable angina pectoris
Renal impairment
Prior MI
PAD
Prior stroke/TIA
Hepatic impairment
Cardiac failure
Others
No RF
1–2 RF
 ¥3 RF
Percent of patients affected
Figure 1 comorbid cardiovascular risk factors and disease.
Abbreviations: LVH, left ventricular hypertrophy; Mi, myocardial infarction; PAD, peripheral arterial disease; TiA, transient ischemic attack; RF, risk factors.
Table 3 shift table for added antihypertensive treatment at baseline and for cumulative changes at the last documented visit (safety population)
Olmesartan-amlodipine   
20/5 mg at last  
documented visit
Olmesartan-amlodipine   
40/5 mg at last  
documented visit
Olmesartan-amlodipine   
40/10 mg at last  
documented visit
Total  
(baseline)*
n % n % n % n %
Olmesartan-amlodipine  
20/5 mg at baseline
2877 37.0 817 10.5 301 3.8 3955 51.4
Olmesartan-amlodipine  
40/5 mg at baseline
132 1.7 1736 22.3 538 6.9 2406 31.0
Olmesartan-amlodipine  
40/10 mg at baseline
50 0.6 77 0.9 1233 15.8 1360 17.5
Total (follow-up) 3059 39.4 2630 33.8 2072 26.6
Note: *Add up to 99.9% because of rounding.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Figure 2 Blood pressure lowering with respect to blood pressure category at baseline. 
Notes: *P , 0.01; **P , 0.0001. 
Abbreviations: HT, hypertension; isH, isolated systolic hypertension.
Table 4 Blood pressure reduction in seRVe* and the randomized controlled trial cOAcH4
∆ Systolic BP ∆ Diastolic BP
SERVE P value  
versus  
baseline
SERVE  
subgroup**
COACH SERVE P value  
versus  
baseline
SERVE 
subgroup**
COACH
BP at baseline 161.8 ± 16.6 166.3 ± 15.4 163.8 ± 16.1 93.6 ± 10.2 108.0 ± 5.9 101.6 ± 5.2
Olmesartan- 
amlodipine 20/5 mg
−27.6 ± 16.3 
(n = 3254)
,0.0001 −31.9 ± 15.4 
(n = 989)
−23.6 ± 14.9 
(n = 160)
−13.2 ± 10.6 
(n = 3254)
,0.0001 −19.5 ± 8.1 
(n = 989)
−14.0 ± 9.1 
(n = 160)
Olmesartan- 
amlodipine 40/5 mg 
−29.5 ± 16.5 
(n = 2749)
,0.0001 −33.0 ± 15.2 
(n = 766)
−25.4 ± 14.7 
(n = 157)
−13.5 ± 10.5 
(n = 2749)
,0.0001 −18.8 ± 8.1 
(n = 766)
−15.5 ± 8.2 
(n = 157)
Olmesartan- 
amlodipine 40/10 mg 
−31.0 ± 18.8 
(n = 2083)
,0.0001 −35.0 ± 18.0 
(n = 467)
−30.1 ± 15.9 
(n = 161)
−14.1 ± 11.7 
(n = 2083)
,0.0001 −19.8 ± 9.7 
(n = 467)
−19.0 ± 8.9 
(n = 161)
Note: *Assignment to dose was based on the previous visit. **SERVE patients complying with the COACH in- and exclusion criteria.
Abbreviation: BP, blood pressure.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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efficacy of olmesartan-amlodipine. In contrast, efficacy was 
nominally higher in patients without previous/concomitant 
antihypertensive medication than in those with prior medi-
cation (−34.3 ± 17.4 versus −28.9 ± 16.9 mmHg systolic 
and −17.5 ± 11.0 versus −13.3 ± 10.7 mmHg diastolic).
At the final visit (usually 12–18 weeks after enrolment), 
there was a strong shift in the ESH/ESC categorization 
 ( Figure 3), with 69.4% of patients (4.3% at baseline) having 
only high normal BP (18.4% isolated systolic hypertension; 
19.1% at baseline). Patients with isolated systolic hyperten-
sion at the final visit usually had had moderate to severe 
hypertension at baseline, while patients with isolated systolic 
hypertension at baseline usually were categorized as being 
high-normal at the final visit.
Tolerability
Adverse drug reactions occurred in a total of 227 patients 
during the study, representing 2.76% of all included patients 
(Table 5). Of all adverse drug reactions, 213 were assessed 
as nonserious and 13 as serious by the reporting physicians. 
The status of seriousness was not assessable due to a lack of 
data in one case. Within this study, three deaths have been 
reported. None of them was related to the study medication 
according to the judgment of the treating physicians.
Table 6 shows an overview of all reported events, clustered 
and coded according to MedDRA (12.0; MedDRA MSSO, 
Berlin, Germany). In total, 338 events were reported, the 
largest number (147) within the system organ class “General 
disorders and administration site conditions” harboring the 
lowest level term “peripheral edemas”; 31.5% of all reported 
adverse drug reactions were peripheral edema in 111/8237 
patients. These results are in agreement with the physicians’ 
assessment of tolerability which was “very good” (70.7%) or 
“good” (25.6%) in the majority of treated patients.
Discussion
There is substantial cardiovascular risk conferred by the 
presence of arterial hypertension, which has been shown 
to be reduced in patients with adequate BP control using 
antihypertensive medication. A fixed-dose combination of 
olmesartan-amlodipine, which was documented to be effec-
tive and well tolerated in previous randomized, controlled 
trials,4,7–12 has been observed under clinical practice condi-
tions in the present study for a 12–18 week period resulting 
in the documentation of a strong BP lowering with high 
tolerability.
Blood pressure lowering in perspective
The results of SERVE conducted in the real-life situation 
include a strong reduction of BP in hypertensive patients by 
29.0 ± 17.1/13.5 ± 10.9 mmHg (P , 0.0001 versus base-
line) with a clear correlation between BP at baseline and BP 
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  reduction (Spearman’s Rho −0.811 for systolic BP and −0.759 
for diastolic BP) and a dependency on dose and prior antihy-
pertensive therapy, but not on age, gender, body mass index, 
duration of hypertension, or the presence of diabetes. After a 
usual treatment duration of 12–18 weeks, 69.4% of patients 
managed to attain the high-normal BP level.
The study results at the final visit (Table 4) should be 
interpreted in comparison with the results of the recent 
randomized, controlled COACH (Counseling Older Adults 
to Control Hypertension) trial4 based on the respective dose 
level of the fixed combination. COACH had a follow-up 
of eight weeks. Mean systolic BP reductions achieved are 
nominally higher in SERVE than in COACH, with   differences 
being more pronounced in the lower dose range (olmesartan-
amlodipine 20/5 mg). On the other hand, the reduction of 
diastolic BP was stronger in COACH than in SERVE. There 
are a variety of reasons that might account for the observed 
differences in BP reduction, even beyond differences in 
patient characteristics outlined in Table 7. First and foremost, 
mean BP at baseline was 161.8/93.6 mmHg in SERVE and 
163.6/101.5 mmHg in COACH, indicating similar systolic 
but substantial differences in diastolic BP. This would argue 
for a stronger reduction of diastolic BP in COACH, because 
the fall in diastolic BP is strongly related to baseline BP. 
Second, the values obtained in SERVE have been obtained 
on the background of a variety of different drugs. The fixed 
Table 5 number of patients with an adverse drug reaction in the observation period
Total population  
(n = 8237)
O20, A5  
(patients, n)
O40, A5  
(patients, n)
O40, A10  
(patients, n)
Total  
(patients, n)
Patients without ADR 4141 2472 1400 8013
Patients with ADR 91 54 79 226*
  serious 5 4 3 13
  not serious 86 50 76 213
Change in dose* O20, A5  
(n, % of patients  
with ADRs)
O40, A5 
(n, % of patients  
with ADRs)
O40, A10 
(n, % of patients  
with ADRs)
Total 
(n, % of patients 
with ADRs)
  not changed 3 (1.33) 4 (1.78) 4 (1.78%) 11 (4.89%)
  Drug withdrawn 86 (38.22) 49 (21.78) 68 (30.22%) 204 (90.67%)**
  Dose reduced 1 (0.44) 1 (0.44) 6 (2.67%) 8 (3.56%)
  Dose increased 1 (0.44) 0 (0) 0 (0%) 1 (0.44%)
  Unknown 0 (0) 0 (0) 1 (0.44%) 1 (0.44%)
Notes: *Data from one patient not included; **One patient with unknown dose.
Abbreviation: ADRs, adverse drug reactions.
Table 6 Adverse drug reactions coded according to MedDRA® Version 12.0
Total population (n = 8237)
MedDRA® primary system organ classes (SOC)
O20, A5 O40, A5 O40, A10 Total
Total number of ADRs, n (%) 140 (41.42) 76 (22.49) 121 (35.80%) 338 (100%)*
  cardiac disorders 2 (0.59) 2 (0.59) 3 (0.89%) 7 (2.07%)
  ear and labyrinth disorders 1 (0.30) 1 (0.30) 1 (0.30%) 3 (0.89%)
  eye disorders 2 (0.59) 0 (0) 3 (0.89%) 5 (1.48%)
  gastrointestinal disorders 18 (5.33) 12 (3.55) 6 (1.78%) 36 (10.65%)
  general disorders and administration site conditions 45 (13.31) 36 (10.65) 65 (19.23%) 147 (43.49%)*
  Hepatobiliary disorders 1 (0.30) 0 (0) 0 (0%) 1 (0.30%)
  immune system disorders 1 (0.30) 0 (0) 0 (0%) 1 (0.30%)
  infections and infestations 0 (0) 0 (0) 1 (0.30%) 1 (0.30%)
  investigations 3 (0.89) 2 (0.59) 0 (0%) 5 (1.48%)
  Metabolism and nutrition disorders 2 (0.59) 0 (0) 0 (0%) 2 (0.59%)
  Musculoskeletal and connective tissue disorders 4 (1.18) 3 (0.89) 8 (2.37%) 15 (4.44%)
  nervous system disorders 27 (7.99) 4 (1.18) 8 (2.37%) 39 (11.54%)
  Psychiatric disorders 3 (0.89) 1 (0.30) 9 (2.66%) 13 (3.85%)
  Reproductive system and breast disorders 2 (0.59) 0 (0%) 2 (0.59%) 4 (1.18%)
  Respiratory, thoracic and mediastinal disorders 8 (2.37) 4 (1.18) 2 (0.59%) 14 (4.14%)
  skin and subcutaneous tissue disorders 13 (3.85) 4 (1.18) 7 (2.07%) 24 (7.10%)
  Vascular disorders 8 (2.37) 7 (2.07) 6 (1.78%) 21 (6.21%)
Note: *One patient each with unknown dose.
Abbreviation: ADRs, adverse drug reactions.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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combination could be added to an existing antihypertensive 
drug therapy and even used in treatment-naïve patients (which 
would not have been on-label). Third, the comparison is based 
on pharmacotherapy at baseline, and most of the patients were 
uptitrated and others were downtitrated. This also might result 
in a bias of the overall results towards higher BP reductions, 
in particularly at low doses.
While a detailed comparison of BP-lowering efficacy on 
a patient basis between SERVE and COACH is beyond the 
scope of the present analysis, the results strongly suggest 
that BP observed in clinical trials is similar to that found in 
primary care, and point to the possibility of adjusting BP 
effectively with the fixed-dose combination with the benefit 
of the known advantages of fixed-dose combinations, such 
as convenient use and increased patient compliance.
Tolerability of fixed-dose combination
The adverse event profile of olmesartan has been analyzed 
in placebo-controlled trials over two years of treatment, with 
more than 3000 patients showing good tolerability.13,14 On 
the other hand, dihydropyridine calcium channel blockers, 
such as amlodipine, have been associated with peripheral 
edema, which is likely to result from preferential arteriolar 
vasodilation and an increase in the pressure gradient between 
the arteriolar and venular capillaries, leading to exudation 
of interstitial fluid.15,16
Data from the recent randomized controlled COACH 
trial4 testing amlodipine up to 10 mg and/or olmesartan up to 
40 mg versus placebo suggest an amelioration of peripheral 
edema with the combined use of amlodipine and olmesar-
tan. While 36.8% of patients on 10 mg amlodipine (18.5% 
with 40 mg olmesartan) experienced edema, the incidence 
was reduced to 23.5% in patients receiving a combination 
at the same doses. This is thought to be the result of lower 
precapillary resistance, normalized intracapillary pressure, 
and reduced fluid exudation with the use of the angiotensin 
receptor blocker.15,17
In this observational study, 2.76% of patients had adverse 
drug reactions, of which about one-third (31.5% of the 
aforementioned 2.76%) were peripheral edema, suggesting 
a substantially lowered risk of edema in clinical practice, or 
a lower vigilance of physicians in primary care for this side 
effect, questioning its clinical relevance. Differences in the 
incidence of edema may also be somewhat related to the 
overall treatment duration. While an incidence rate of 23.5% 
was reported for the first randomized, controlled eight-week 
phase of COACH,4 an incidence rate of only 14.5% was 
reported for the 44-week open-label extension.8 It may also 
be related to a certain degree of underreporting in trials such 
as SERVE, in which physicians were not specifically asked 
whether edema had been present or not, as opposed to COACH 
in which there were specific questions addressing this issue.
Limitations
The present study has the inherent limitations of noninter-
ventional studies, including lack of a control group and no 
randomization. Therefore, the BP lowering reported may 
be a higher estimate than the true effect. On the other hand, 
the study documented a substantial BP reduction across 
a wide range of different patients, of which a proportion 
would not qualify for a randomized controlled trial such 
as COACH, because of comorbid disease and concomitant 
pharmacotherapy (Table 4). Therefore, this kind of study 
is of particular importance when targeting a high external 
validity, and reflects actual clinical practice to a far greater 
extent than randomized trials.
Conclusion
The fixed-dose combination of olmesartan and amlodipine 
was effective and well tolerated in an unselected population 
Table 7 comparison of inclusion and exclusion criteria for the 
seRVe and cOAcH studies4,8
COACH 
(Randomized,  
controlled trial)
SERVE 
(Noninterventional  
study)
inclusion Men or women $ 18 years Men or women $ 18 years
seated DBP $ 95 mmHg  
and #120 mmHg;  
difference #10 mmHg  
between 2 measurements
essential hypertension  
uncontrolled
exclusion DBP . 120 mmHg
History of cardiovascular 
disease
cardiogenic shock, acute 
Mi (,4 weeks), unstable 
angina
Uncontrolled diabetes severely reduced liver 
function and biliary duct 
obstruction
smoking . one pack  
of cigarettes
Laboratory values or 
systemic disease  
considered clinically  
significant by the  
investigator
Taking any medication  
that could interfere with  
the objectives of the study
Pregnancy and nursing 2nd and 3rd trimester  
of pregnancy
Abbreviations: DBP, diastolic blood pressure; Mi, myocardial infarction; cOAcH.Vascular Health and Risk Management
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of patients in primary care practice. These results confirm 
prior randomized controlled trial evidence.
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